Worth the Weight? Rethinking GLP-1 Injections

Weight loss medications have moved far beyond the clinic, slipping into everyday life and discussed as casually as skincare or supplements. For many, they offer the possibility of shedding the pounds without the exhausting cycle of restraint and regain. And in the right setting, they are effective. But as with anything that rises this quickly, the narrative can become simplified. Benefits are amplified, nuance gets lost and some of the more complex, emerging risks are only just beginning to enter the conversation.

Extremely Rare But Serious Concern

One of the more concerning developments being explored within ophthalmology is a rare association between GLP-1 receptor agonists and non-arteritic anterior ischaemic optic neuropathy (NAION).

This is not a new condition and is something we see in emergency eye clinics, most often in older individuals with underlying vascular risk factors. It occurs when blood flow to the optic nerve is compromised, leading to sudden, painless vision loss in one eye. Classically, patients notice a shadow or absence in the lower half of their visual field. What makes it particularly distressing is that the damage is permanent.

Historically, NAION has been linked to conditions such as hypertension, diabetes and sleep apnoea. More recently, however, attention has turned towards GLP-1 medications. At present, it is important to be precise. This is not proven causation, and extremely rare, but in medicine, even the suggestion of a link to irreversible vision loss is enough to warrant careful scrutiny and open discussion.

According to the Medicines & Health Products Regulation Agency, "semaglutide treatment has, in extremely rare cases, been linked to a serious eye condition called NAION". And that, "if you notice a change in your eyesight, such as sudden blindness or your eyesight gets worse very quickly in one or both of your eyes during treatment with semaglutide, urgently attend eye casualty (if available in your area) or A&E."

The Trade-Off: What Weight Loss Really Means

Weight loss is often spoken about as though it is a uniform good. But biologically, it is more complicated than that. Shedding the pounds on these medications means you are not losing fat alone. A proportion of that loss comes from lean tissue, including muscle.

In younger people this may be less immediately apparent, but in midlife and beyond, it carries greater significance. Muscle mass underpins metabolic health, physical resilience and long-term weight stability. Losing it can subtly shift the trajectory of ageing in ways that are not always obvious at the outset.

This is where the conversation needs to widen. Because the number on the scales doesn’t tell us what’s really happening in the body – and health is always more complex than weight alone.

What Happens Next?

Another reality is what happens when treatment stops. For many, these medications are effective precisely because they are active. Appetite is regulated, satiety signals change and food noise quietens. But once withdrawn, those mechanisms often return.

Weight regain is not unusual, and in some cases can be rapid. This raises a more difficult question: Are these drugs a temporary intervention, or are they, in effect, a long-term commitment? That distinction matters, and it is not always fully explored at the beginning of treatment.

Alongside these broader considerations are the more established side effects that accompany GLP-1 medications. Gastrointestinal symptoms are the most common, and for some, the most limiting. Nausea, altered bowel habits and a general sense of digestive discomfort can persist beyond the initial adjustment period. More rarely, but more seriously, there is the risk of pancreatitis and gallbladder disease, both of which require prompt medical attention.

There is also a psychological dimension. Rapid weight loss can change not just the body, but the relationship a person has with food, appetite and control. For some, it feels liberating; for others, more complicated.

A More Balanced Conversation

None of this diminishes the value of these medications when used appropriately. For patients with type 2 diabetes, or those with obesity-related health risks, GLP-1 receptor agonists can be genuinely life-changing.

But they are not a cosmetic shortcut and are not without consequence.

What’s needed now is a more balanced conversation. One that moves beyond before-and-after images and considers the full clinical picture. Who is this right for? What are the trade-offs? What does long-term use look like? And what happens if it stops? Those are the questions patients are increasingly asking.

So If Not Weight Loss Jabs… What Then?

This is a question that is now coming up more and more often. If the answer isn’t simply medication, then what does sustainable weight management actually look like? The reality is that it is rarely one thing. It sits at the intersection of metabolic health, hormonal balance, nutrition, movement and behaviour, layered with the realities of midlife physiology.

It’s a conversation I’ll be exploring in more depth in an upcoming podcast with Dr Paul Barrington Chell, who has co-authored Beyond Weight Loss with Dr Monique Hope-Ross. Together, through Healthbuddi, they take a broader view of health – one that looks beyond short-term solutions towards something more sustainable.

GLP-1 medications have undoubtedly changed the landscape of weight loss, but when a treatment has the potential to influence not just weight – muscle mass, long-term metabolic patterns and, potentially, even vision – it deserves a more considered discussion. And this is why patients don’t just need access to them, they need the full picture.